leadf
logo-loader
viewXPhyto Therapeutics Corp.

XPhyto Therapeutics acquires German narcotics company Vektor

Vektor specializes in thin therapeutic films, such as skin patches and oral strips, and possesses a slate of narcotics licenses

Cannabis in a shopping cart
XPhyto also owns Bunker Pflanzenextrakte GmbH, a German cannabis cultivation and extraction company

XPhyto Therapeutics Corp (CSE:XPHY), a medical cannabis company, announced a deal Monday to acquire Vektor Pharma TF GmbH, a German narcotics manufacturer.

Through a definitive share purchase agreement, XPhyto will pay roughly $515,540 in cash, plus 200,000 shares of stock, about $589,188 in units of capital, and issue a pair of convertible debentures  worth $294,594 and $220,945 respectively.

The capital units, worth $1 each, equate to one common share and one purchase warrant exercisable into one common share of the company at an price of C$1.00 per share for a period of three years from closing.

READ: XPhyto Therapeutics signs new research agreement with leading German university

Vektor specializes in thin therapeutic films, such as skin patches and oral strips, and possesses a slate of narcotics licenses covering traditional and cannabis-related medications.  

"XPhyto is building a next generation cannabis company focused on medical formulation, clinical validation and emerging European markets," XPhyto CEO Hugh Rogers said in a statement. 

"We believe that Vektor will add significant long-term value at every level of our business, from clinical trial expertise and drug manufacturing capability to their German cannabis and narcotics import licences and strong relationships with the German health authority," Rogers said.

The agreement is expected to close by September 16 and is subject to regulatory approval.

XPhyto is based in Vancouver, but has its sights set on European markets. The company also owns Bunker Pflanzenextrakte GmbH, a German cannabis cultivation and extraction company. 

The company's stock held flat at $1.30 on Monday.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: XPhyto Therapeutics Corp.

Price: 2.3 CAD

CSE:XPHY
Market: CSE
Market Cap: $139.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

XPhyto Therapeutics continues to move toward commercialization of their...

XPhyto Therapeutics (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide an update on their plans to go to market in Europe with their testing program for the COVID-19 Rogers talks about where that program is AT and also about their drug delivery platform...

on 11/04/2020

2 min read